Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Google Scholar citation report
Citations : 790
Clinical Pharmacology & Biopharmaceutics received 790 citations as per Google Scholar report
Clinical Pharmacology & Biopharmaceutics peer review process verified at publons
Indexed In
- CAS Source Index (CASSI)
- Index Copernicus
- Google Scholar
- Sherpa Romeo
- Genamics JournalSeek
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- Publons
- Euro Pub
- ICMJE
Useful Links
Recommended Journals
Related Subjects
Share This Page
Cost-effectiveness analysis of additional Bevacizumab to chemotherapy for malignant pleural mesothelioma from a Chinese perspective
4th International Pharma & Clinical Pharmacy Congress
Mei Zhan
West China Hospital, China
Posters & Accepted Abstracts: Clin Pharmacol Biopharm
Abstract
Objective: To evaluate the cost-effectiveness of addition of bevacizumab to pemetrexed plus cisplatin (PC) for malignant pleural mesothelioma (MPM) following a phase III trial that show an overall survival (OS) benefit with the addition of bevacizumab. Methods: A Markov decision tree based on the mesothelioma avastin cisplatin pemetrexed study (MAPS) was created, comparing bevacizumab+PC to PC alone. Three health states (progression-free survival, progressive disease and death) were analyzed in a Markov model. The costs were calculated from the Chinese societal perspective. Results were reported in qualityadjusted life year (QALY) and incremental cost-effectiveness ratios (ICERs). Results: Bevacizumab+PC came at an ICER of $323343.46 per QALY, which are much more than the accepted willingness-topay (WTP) threshold of $23970.00 per QALY in China. Conclusions: Addition of bevacizumab to PC is not a cost-effective first-line treatment for MPM when compared with PC in China.Biography
Mei Zhan has graduated from Sichuan University and currently working as a Clinical Pharmacist in West China Hospital of Sichuan University. She has published more than 17 papers in journals of repute.
Email: mandyzhanmei@163.com
